Ligand Pharmaceuticals Incorporated LGND
301.52
2.48
0.83%
as of 25 Sep
- Market cap
- $6.1B
- P/E
- 30.1×
Follow LGND
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
74.12 | 30.01 | 25.47 | 31.58 |
P/S ratio |
13.80 | 13.64 | 14.46 | 21.83 | |
P/FCF ratio |
136.42 | 60.02 | 29.50 | 44.23 | |
P/Operating CF |
264.94 | 79.63 | 81.53 | 264.04 | |
P/B ratio |
3.65 | 3.59 | 3.98 | 6.55 | |
Price to Tangible BV |
5.64 | 5.30 | 5.85 | 9.66 | |
EV/Sales |
12.88 | 12.48 | 13.21 | 20.99 | |
EV/EBITDA |
66.00 | 47.07 | 29.20 | 49.08 | |
EV/Operating CF |
101.41 | 67.79 | 29.35 | 46.29 | |
EV/FCF |
127.32 | 54.93 | 26.93 | 42.53 | |
Quick Ratio |
24.07 | 21.83 | 20.81 | 30.83 | |
Current Ratio |
24.69 | 22.23 | 21.28 | 31.18 | |
Net Debt/EBITDA |
(3.71) | (15.05) | (13.85) | (14.86) | |
Debt/Assets |
30.17% | 28.59% | 29.17% | 51.54% | |
Debt/Equity |
0.47 | 0.44 | 0.45 | 1.16 | |
Asset Turnover |
0.21 | 0.21 | 0.23 | 0.19 | |
Operating CF/Net income |
0.11 | 1.03 | (3.65) | 0.50 | |
Capex/Depreciation |
0.13 | 0.03 | 0.90 | (0.02) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
18.20% | 5.88% | 4.15% | 23.03% | |
Selling, General and Administrative Expense of Revenue |
24.64% | 41.95% | 40.28% | 45.72% | |
Intangible Assets out of Total Assets |
0.23 | 0.21 | 0.21 | 0.14 | |
Share Based Compensation of Revenue |
12.77% | 23.92% | 20.49% | 21.44% | |
Graham Net Nets |
0.07 | 0.08 | 0.08 | 0.04 | |
Graham Number |
51.09 | 86.35 | 94.06 | 104.22 | |
Earnings Yield |
1.35% | 3.33% | 3.93% | 3.17% | |
Free Cash Flow Yield |
0.73% | 1.67% | 3.39% | 2.26% | |
Revenue per Share |
5.90 | 3.09 | 2.60 | 3.17 | |
Operating CF per Share |
0.67 | 2.37 | 2.45 | 1.20 | |
Capex per Share |
0.05 | 0.01 | 0.34 | (0.01) | |
Free Cash Flow per Share |
0.72 | 2.38 | 2.79 | 1.19 | |
Cash per Share |
34.58 | 39.11 | 39.81 | 68.32 | |
Shareholders Equity per Share |
48.53 | 52.60 | 50.16 | 48.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
48.53 | 52.60 | 50.16 | 48.22 | |
Free Cash Flow |
14.08 | 46.12 | 55.44 | 23.87 | |
Working Capital |
723.38 | 794.82 | 824.75 | 1,410.38 | |
Capital Expenditures |
0.99 | 0.20 | 6.75 | (0.14) | |
Net Current Asset Value |
227.32 | 288.85 | 330.63 | 238.76 | |
EV/EBIT |
184.72 | 81.61 | 38.32 | 64.37 | |
Capex to Sales |
(0.01) | 0.00 | (0.13) | 0.00 | |
Net Profit Margin |
101.57% | 75.06% | (25.80%) | 76.16% | |
Price to Operating Income |
197.93 | 89.17 | 41.97 | 66.94 | |
| Other line items | |||||
Average Receivables |
50.11 | 51.75 | 48.81 | 61.16 | |
Average Payables |
4.19 | 4.24 | 5.32 | 8.99 | |
Average Inventory |
14.32 | 11.62 | 13.94 | 12.88 | |
Average Assets |
1,215.82 | 1,251.21 | 1,218.77 | 1,567.24 | |
Average Common Equity |
895.67 | 923.83 | 896.43 | 898.02 |
Columns are period end dates